Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,558
datasets available to search
ShareScore release 0.9.0
Dataset results
1,558 results for “Chronic Kidney Disease”
Low Energy Shockwave Therapy (LE-SWT): A Novel Treatment for Chronic Kidney Disease
ClinicalTrials.gov study NCT02515461. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Low Protein Diet, Gut Microbiome and Chronic Kidney Disease
ClinicalTrials.gov study NCT05019599. IPD Sharing: NO. Countries: 1. Publications: 1.
A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients
ClinicalTrials.gov study NCT00679991. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The Impact of Pharmacist-led Mobile Application on Adherence in Chronic Kidney Disease Patients
ClinicalTrials.gov study NCT05168449. IPD Sharing: NO. Countries: 1. Publications: 1.
Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
ClinicalTrials.gov study NCT00811889. IPD Sharing: YES. Countries: 1. Publications: 3.
A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and Hig
ClinicalTrials.gov study NCT06742723. IPD Sharing: YES. Countries: 42. Publications: 1.
Inspiratory Muscle Training for Chronic Kidney Disease Patients on Hemodialysis
ClinicalTrials.gov study NCT05241652. IPD Sharing: Not stated. Countries: 1. Publications: 11.
Effect of Bee Venom on Chronic Kidney Disease-Mineral Bone Disorders in Hemodialysis Patients: a Randomized Controlled Trial
ClinicalTrials.gov study NCT06901102. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Data from: Global prevalence of chronic kidney disease: a systematic review and meta-analysis
Open the record for dataset details and reuse information.
Data from: Skin autofluorescence and subclinical atherosclerosis in mild to moderate chronic kidney disease: a case-control study
Open the record for dataset details and reuse information.
Association of chronic inflammation and accelerated atherosclerosis among an indigenous black population with chronic kidney disease
<p>Introduction: Inflammation plays a major role in the development of atherosclerosis and cardiovascular morbidity and mortality in chronic kidney disease (CKD) patients. Toll-like receptor-4 (TLR4) is a major receptor for lipopolysaccharides (endotoxin) and other ligands involved in the pathogenesis of inflammation. We determined whether endotoxin levels and the presence of TLR4 polymorphisms are associated with markers of inflammation and atherosclerosis among South African CKD patients.</p> <p><br> Materials and methods: Endotoxin, lipopolysaccharide binding protein (LBP), serum CD14 (sCD14), interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1) and carotid intima media thickness (CIMT) were measured in 160 participants (120 CKD patients and 40 controls). Associations between endotoxins and CIMT in the presence of sCD14, IL-8 and MCP-1, were assessed using odds ratios. Participants were screened for the presence of Asp299Gly and Thr399Ile TLR4 polymorphisms, and CIMT and inflammatory markers were compared between subjects with and without TLR4 polymorphisms.</p> <p>Results: Endotoxin levels correlated with sCD14 (r=0.441, p<0.001) and MCP-1 (r=0.388, p<0.001) levels while increased CIMT was associated with MCP-1 (r=0.448, p<0.001), sCD14 levels (r=0.476, p<0.001), LBP (r=0.340, p<0.001), and IL-8 (r=0.395, p<0.001). Atherosclerosis was associated with endotoxin levels (odds ratio: 4.95; 95% confidence interval: 2.52-9.73; p<0.001), and was predicted by higher serum levels of inflammatory markers. Analysis of patients with TLR4 polymorphisms showed reduced serum levels of inflammatory markers and CIMT values compared with the patients carrying the wild type TLR4 alleles.</p> <p>Conclusion: The study demonstrated associations between circulating endotoxaemia, systemic inflammation and accelerated atherosclerosis among South African CKD patients, and showed that the atherogenic predictive power of endotoxaemia was significantly increased by the presence of elevated levels of inflammatory markers. Additional findings, which must be confirmed, suggest that TLR4 polymorphisms are associated with low levels of inflammatory markers and CIMT values.</p>
Data from: Intravenous thrombolysis in patients with chronic kidney disease: A systematic review and meta-analysis
<p><b><span>Objective</span></b><span> We sought to determine the association of chronic kidney disease (CKD) with the safety and efficacy of intravenous thrombolysis (IVT) among acute ischemic stroke (AIS) patients.</span></p> <p><b><span>Methods</span></b><span> Systematic review and pairwise meta-analysis of studies involving patients with CKD undergoing IVT for AIS were conducted to evaluate the following outcomes: symptomatic intracranial hemorrhage (sICH), asymptomatic and any ICH, in-hospital and 3-month mortality, </span>3-month favorable functional outcome (FFO, mRS 0-1) and <span>3-month functional independence (FI, mRS 0-2). CKD was defined using estimated glomerular filtration rate (eGFR) ranging from mild (eGFR: 60-89ml/min), moderate (eGFR: 30-59ml/min) and severe (eGFR: 15-29ml/min). </span></p> <p><b><span>Results</span></b><span> We identified 20 studies comprising </span>60,486 AIS <span>patients treated with IVT. In unadjusted analyses, CKD was associated with </span>sICH according to NINDS (7 studies; OR=1.41, 95%CI: 1.19–1.67) and ECASS-II (9 studies; OR=1.37, 95%CI: 1.01–1.85) definitions, any ICH (8 studies; OR=1.42, 95%CI: 1.18–1.70), 3-month mortality (9 studies; OR = 2.20, 95%CI: 1.72–2.81)<span>, </span>3-month FFO (8 studies; OR=0.58, 95%CI: 0.47–0.72) and <span>3-month FI</span> (8 studies; OR=0.57, 95%CI: 0.46–0.71). In adjusted analyses, <span>CKD</span> was associated with sICH according to NINDS (4 studies; OR<sub>adj</sub>=1.34, 95%CI: 1.01–1.79) and ECASS-II (3 studies; OR<sub>adj</sub>=2.08, 95%CI 1.27–3.43) definitions, any ICH (6 studies; OR<sub>adj</sub>=1.41, 95%CI 1.01–1.97), in-hospital mortality (2 studies; OR<sub>adj</sub> =1.19; 95%CI, 1.09-1.30) and 3-month FFO (6 studies; OR<sub>adj</sub>=0.80, 95%CI 0.70–0.92). </p> <p><b><span>Conclusions</span></b><span> After adjustment for confounders in this pairwise meta-analysis, moderate-severe CKD is associated with increased risks of intracranial hemorrhage and worse functional outcomes among AIS patients treated with IVT. </span></p>
Comparison of health literacy profile of patients with end stage kidney disease on dialysis versus non-dialysis chronic kidney disease and the influencing factors: a cross-sectional study
<p><strong>Objectives</strong>: Lower health literacy (HL) is associated with poor outcomes in patients with kidney disease. Since HL matches the patient's competencies with the complexities of the care package, the level of HL sufficient in earlier stages of chronic kidney disease (CKD) may be inadequate for end-stage kidney disease (ESKD) patients on dialysis. We aimed to analyse the HL profile of ESKD and non-dialysis CKD patients and examine if there were significant associations with covariates which could be targeted to address HL deficits, thereby improving patient outcomes.</p> <p><strong>Design and setting</strong>: Cross-sectional study of CKD and ESKD patients from a single Australian health district.</p> <p><strong>Methods</strong>: We assessed the HL profile of 114 CKD and 109 ESKD patients using a 44-item multi-domain HL Questionnaire (HLQ) and examined its association with demographic factors (age, gender, race), smoking, income, education, comorbidities, carer status, cognitive function and depression. Using multi-variable logistic regression models, HL profiles of CKD and ESKD patients were evaluated after adjusting for covariates.</p> <p><strong>Results</strong>: Patients with ESKD had similar demographics and educational levels compared to CKD patients. ESKD had significantly higher frequency of vascular disease, cognitive impairment and depression. ESKD patients had better HL scores for the social support domain (37.1% vs 19.5% in higher HLQ4 tertile, p=0.004), whereas all other HL domains including engagement with healthcare providers were comparable to CKD. Depression was independently associated with nearly all of the HL domains (HLQ1: OR 2.6, p=0.030, HLQ2: OR 7.9, p=<0.001, HLQ3: OR 7.6, p<0.001, HLQ4: OR 3.5, p=0.010, HLQ5: OR 8.9, p=0.001, HLQ6: OR 3.9, p=0.002, HLQ7: OR 4.8, p=0.001, HLQ8: OR 5.3, p=0.001) and education with HL domains relevant to processing health related information (HLQ8: OR 2.6, p=0.008, HLQ9: OR 2.5, p=0.006).</p> <p><strong>Conclusions</strong>: Despite very frequent interactions with health systems, ESKD patients on dialysis did not have higher HL in engagement with health providers and most other HL domains, compared to CKD patients. Strategies promoting patient-provider engagement and managing depression which strongly associates with lower HL may address the impact of HL deficits and favourably modify clinical outcomes in renal patients. </p>
Figure 4 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
Figure 4 Influence of NAG and COR on kidney AOS indices in rats with CRF, M±SEM.Notes. a – p < 0.05 compared to the intact control group; b – p < 0.05 compared to the control pathology group (ANOVA, Dunnett's post-hoc test); n – amount of animals at the end of experiment.
Figure 2 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
Figure 2 Influence of NAG and COR on proteinuria in rats with CRF, M±SEM. Notes. a – p < 0.05 compared to the intact control group; b – p < 0.05 compared to the control pathology group; c – p < 0.05 compared to the NAG-treated group (ANOVA, Dunnett's post-hoc test); n – amount of animals at the end of experiment.
Figure 1 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
Figure 1 Influence of NAG and COR on survival of rats with CRF. Notes. a – p < 0.05 compared to the intact control group; b – p < 0.05 compared to the control pathology group (Fisher's exact test); n – amount of animals at the end of experiment.
Figure 3 from: Shebeko S, Zupanets I, Otrishko I (2020) Efficacy of the N-acetylglucosamine in experimental therapy of chronic kidney disease. Pharmacia 67(4): 253-259. https://doi.org/10.3897/pharmacia.67.e38078
Figure 3 Urinary excretion of creatinine (A) and urea (B) under the influence of NAG and COR in rats with CRF, M±SEM. Notes. a – p < 0.05 compared to the intact control group; b – p < 0.05 compared to the control pathology group; c – p < 0.05 compared to the NAG-treated group (ANOVA, Dunnett's post-hoc test); n – amount of animals at the end of experiment.
Data from: Provision of care for chronic kidney disease by non-nephrologists in a developing nation: a national survey
Objectives The prevalence of chronic kidney disease (CKD) in developing countries has increased dramatically. This study aimed to explore the practice patterns of non-dialysis-dependent CKD care in an affluent developing country. Settings Primary and specialised healthcare facilities of public and private sectors in the United Arab Emirates. Participants 159 non-nephrologist physicians practising in the United Arab Emirates. Interventions A 28-item online self-administered questionnaire based on CKD clinical practice guidelines. Primary and secondary outcome measures The physicians' approach to identifying and managing patients with CKD. Results The survey was completed by 159 non-nephrologists, of whom 135 reported having treated patients with CKD. Almost all the respondents screen patients with hypertension and diabetes for CKD, but one-third of them do not screen patients with cardiovascular disease and elderly patients for CKD. The use of accurate CKD screening tests (estimated glomerular filtration rate and albumin/creatinine ratio) was suboptimal (77% and 59% of physicians used the procedures, respectively). One-third of the physicians do not offer treatment with inhibitors of the renin–angiotensin system to patients with CKD, and only 66% offer antilipid treatment. In general, the primary healthcare physicians are more familiar than secondary healthcare physicians with the diagnosis and management of patients with CKD. Conclusions We identified substantial physician-declared deficiencies in the practice of identifying and managing early CKD. Integration of quality CKD care within the healthcare system is required to face the increasing burden of CKD in the United Arab Emirates and possibly in other developing nations.
CURRENT APPROACHES TO TREATMENT OF CHRONIC KIDNEY DISEASE COMPLICATED NEPHROGENIC HYPERTENSION
Open the record for dataset details and reuse information.
Machine Learning based Inference System for Diagnosing Chronic Kidney Disease
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.